Vanda Pharmaceuticals INC 8-K filings

Vanda Pharmaceuticals stockholders approved all proposals at the 2026 annual meeting, including director elections and equity plan amendments.

Vanda Pharmaceuticals announced strong first-quarter 2026 results, driven by Fanapt sales growth and the launch of NEREUS, leading to an increase in full-year revenue guidance.

Vanda Pharmaceuticals has expanded its Board of Directors to seven members with the appointment of veteran biotech analyst Dr. Charles Duncan.

Vanda Pharmaceuticals announced FDA approval for BYSANTI (milsaperidone) to treat bipolar I disorder and schizophrenia in adults, marking a significant psychiatric innovation.

Vanda Pharmaceuticals' Compensation Committee approved 2025 bonuses, 2026 salaries, and new equity awards for its named executive officers.

Vanda Pharmaceuticals announced the FDA again rejected its supplemental New Drug Application for HETLIOZ to treat jet lag disorder, citing insufficient evidence despite acknowledging positive efficacy.

Vanda Pharmaceuticals announced FDA approval of NEREUS (tradipitant) for the prevention of vomiting induced by motion, marking the first new pharmacologic treatment in over four decades.

Vanda Pharmaceuticals announced the FDA has lifted a partial clinical hold on its drug tradipitant for motion sickness, following a dispute resolution.

Vanda Pharmaceuticals announced a brief extension for the FDA's re-review of the partial clinical hold on tradipitant, while NDA labeling discussions for motion sickness treatment have begun.

Vanda Pharmaceuticals reported an 18% year-over-year increase in Q3 2025 net product sales, driven by strong Fanapt growth, alongside significant progress in its regulatory pipeline.

Vanda Pharmaceuticals and the U.S. Food and Drug Administration have agreed on a collaborative framework to resolve ongoing disputes concerning HETLIOZ and tradipitant.

Vanda Pharmaceuticals announced second quarter 2025 financial results, showing a 27% increase in Fanapt sales and progress in its pipeline with two NDA acceptances, but also reported a significantly higher net loss and decreased sales for HETLIOZ and PONVORY.

Vanda Pharmaceuticals Inc. announced that its stockholders approved all four proposals at the 2025 Annual Meeting, including the re-election of two Class I directors, ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of executive compensation, and an amendment to the 2016 Equity Incentive Plan.

Vanda Pharmaceuticals announced its Q1 2025 financial results, showcasing increased Fanapt sales and advancements in its drug pipeline.

Vanda Pharmaceuticals announces that the FDA has accepted its new drug application for tradipitant for the treatment of motion sickness, with a target decision date set for December 30, 2025, under the Prescription Drug User Fee Act.

Vanda Pharmaceuticals' Compensation Committee approves 2024 bonuses, 2025 salaries and bonus targets, and RSU awards for named executive officers.

Vanda Pharmaceuticals announces a 17% increase in Q4 2024 total revenues, reaching $53.2 million, and projects continued growth in 2025 with revenues between $210 to $250 million.

Vanda Pharmaceuticals has announced the filing of a new drug application for tradipitant, aimed at treating motion sickness, referencing historical context of motion sickness impact on military operations.

Vanda Pharmaceuticals announced a 23% increase in revenue for the third quarter of 2024 compared to the same period last year, driven by strong performance of Fanapt and the launch of Ponvory.

Vanda Pharmaceuticals' board has rejected a second unsolicited acquisition proposal from Cycle Group Holdings, deeming it an undervaluation of the company.

Vanda Pharmaceuticals has updated its bylaws to clarify procedures for stockholder meetings, director nominations, and other corporate governance matters, effective October 2, 2024.

The FDA has declined to approve Vanda Pharmaceuticals' tradipitant for gastroparesis, requesting additional studies despite existing evidence of efficacy.

Vanda Pharmaceuticals has amended its Rights Agreement to clarify the definitions of 'Acquiring Person', 'Acting in Concert', and 'Beneficial Owner'.

Vanda Pharmaceuticals announced a 10% year-over-year increase in total revenue for Q2 2024, alongside a net loss, and has reinstated its full-year financial guidance.

Vanda Pharmaceuticals' Board of Directors has rejected unsolicited acquisition proposals from Future Pak, LLC and Cycle Group Holdings Ltd, deeming them as substantially undervaluing the company.

Vanda Pharmaceuticals has received a revised unsolicited, non-binding acquisition proposal from Future Pak, LLC for $8.50-$9.00 per share in cash plus Contingent Value Rights.

Vanda Pharmaceuticals has confirmed receiving an unsolicited, non-binding indication of interest from Cycle Group Holdings to be acquired for $8.00 per share in cash.

Vanda Pharmaceuticals' Board of Directors has rejected a revised acquisition proposal from Future Pak, LLC, deeming it substantially undervalues the company and poses significant risks.

Vanda Pharmaceuticals' board of directors has rejected the conditional resignation of director Phaedra S. Chrousos, who received less than a majority of votes at the annual meeting.

Vanda Pharmaceuticals held its 2024 annual meeting where stockholders voted on director elections, auditor ratification, executive compensation, and an amendment to the equity incentive plan.